Subject: Specialised Services Circular (SSC 2585)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
SSC 2585	**Re: NICE Technology Appraisal CDF review termination: tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (Review of TA567)**	University Hospital Bristol and Weston

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? **No**

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

Specialised Commissioning South West
NHS England
360 Bristol
Marlborough Street
Bristol
BS1 3NX
Email: england.speccomm-southwest@nhs.net

30 November 2023

All Chief Executives

All Medical Directors

All Chief Pharmacists

Dear Colleagues,

Re: NICE Technology Appraisal CDF review termination: tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (Review of TA567)

I am writing to advise you regarding the funding position for the NICE Cancer Drugs Fund review for tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies.

NICE has indicated that Novartis has informed them that they will not be providing an evidence submission for this CDF review. Without this evidence of clinical and cost effectiveness, NICE have no option but to proceed to publish terminated guidance. Further information is available here: https://www.nice.org.uk/guidance/ta933

In light of this tisagenlecleucel will cease to be funded from the Cancer Drugs Fund (CDF) from the publication of terminated guidance on 29 November 2023.

Any patients approved for treatment with tisagenlecleucel by the National CAR T Clinical Panel prior to 29 November who have not yet been reinfused may continue their treatment with tisagenlecleucel. The NHS England initiation form TIS02a was withdrawn from Blueteq on 29 November 2023 and the treatment criteria removed from the national CDF list at the same time. The reinfusion form TIS02b will remain available for any patients who have been apheresed and are awaiting reinfusion. The CDF list is available at https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/

In addition, commissioned CAR T centres must:

- Ensure that no new patients are started on tisagenlecleucel following the publication of terminated guidance on 29 November 2023 as there will be no funding available for new patients at that point. Consequently, the CDF will not reimburse any patients who start treatment from this date.
- Ensure they are registering tisagenlecleucel use on SACT. The SACT dataset is a mandated dataset as part of the Health and Social Care Information Standards. This is listed as a Schedule 6 national information requirement within the NHS Standard Contract.

Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at https://nhsengland.sharefile.eu/Authentication/Login

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of this policy nationally and to ensure that no new patients are enrolled following the publication of final guidance.

With best wishes,

Luke Culverwell
Deputy Director of Specialised Commissioning

Tracey Williams
Clinical Pharmacist